Though Phase III trials began while Organon was still a part of Akzo Nobel.[17] Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 people have participated in clinical trials of asenapine, and the FDA approved the manufacturer's NDA in August 2009.[18]